PROFILES - Connect with RTRN Researchers

Vakaramoko Diaby
Title Assistant Professor
Faculty Rank
Degree Ph.D.
Institution Florida A&M University
Department College of Pharmacy and Pharmaceutical Sciences
Clusters Cancer
HIV/AIDS
Women's Health and Reproductive Biology
Address
1520 S MLK Jr. Blvd
Dyson Building Room 200 G
City Tallahassee
State FL
Postal Code 32307
Telephone 8504125712
Fax 8504127548
Email
QR Barcode

Narrative icon

 
Not Available

Publications icon

  Check NIH Public Access Policy Compliance

Loading
Please wait
1. Tran AD, Fogarty G, Nowak AK, Diaby V, Hong A, Watts C, Morton RL. Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases. Appl Health Econ Health Policy. 2020 Mar 11.
2. Wang CY, Pham PN, Kim S, Lingineni K, Schmidt S, Diaby V, Brown J. Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States. Clin Transl Sci. 2020 Mar; 13(2):352-361.
3. Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 Feb 11.
4. Tran PT, Diaby V. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. J Manag Care Spec Pharm. 2020 Feb; 26(2):221.
5. Diaby V, Wang CY, Alqhtani H, van Boemmel-Wegmann S, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting. Data Brief. 2020 Apr; 29:105194.
6. Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2020 Feb; 49:141-148.
7. Xiao H, Jiang X, Chen C, Wang W, Wang CY, Ali AA, Berthe A, Moussa RK, Diaby V. Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study. Res Social Adm Pharm. 2019 Nov 18.
8. Baltussen R, Marsh K, Thokala P, Diaby V, Castro H, Cleemput I, Garau M, Iskrov G, Olyaeemanesh A, Mirelman A, Mobinizadeh M, Morton A, Tringali M, van Til J, Valentim J, Wagner M, Youngkong S, Zah V, Toll A, Jansen M, Bijlmakers L, Oortwijn W, Broekhuizen H. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. Value Health. 2019 Nov; 22(11):1283-1288.
9. Shah CH, Balkrishnan R, Diaby V, Xiao H. Examining factors associated with adherence to hormonal therapy in breast cancer patients. Res Social Adm Pharm. 2020 Apr; 16(4):574-582.
10. Diaby V, Ali AA, Montero AJ. Value Assessment Frameworks in the United States: A Call for Patient Engagement. Pharmacoecon Open. 2019 Mar; 3(1):1-3.
11. Ali AA, Tawk R, Xiao H, Campbell E, Semykina A, Montero AJ, Mogos M, Diaby V. Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data. Cancer Med. 2019 01; 8(1):117-127.
12. Xiao H, Jiang X, Chen C, Montero AJ, Diaby V. Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review. Pharmacoecon Open. 2018 Dec; 2(4):359-369.
13. Okere AN, Ezendu K, Berthe A, Diaby V. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2018 Feb; 24(2):142-152.
14. Okere AN, Montesdeoca J, Glasper A, Diaby V. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review. Curr Diabetes Rev. 2018; 14(4):363-375.
15. Diaby V, Ali AA, Williams KJ, Ezendu K, Soto-Perez-de-Celis E, Chavarri-Guerra Y, de Lima Lopes G. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast Cancer Res Treat. 2017 Dec; 166(3):951-963.
16. Ali AA, Xiao H, Tawk R, Campbell E, Semykina A, Montero AJ, Diaby V. Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Curr Med Res Opin. 2017 02; 33(2):391-400.
17. Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 11; 160(1):187-196.
18. Boulin M, Diaby V, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. PLoS One. 2016; 11(9):e0162951.
19. Diaby V, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin. 2016 06; 32(6):991-6.
20. Diaby V, Sanogo V, Moussa KR. ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare. Expert Rev Pharmacoecon Outcomes Res. 2016; 16(1):141-7.
21. Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015 May; 151(1):27-40.
22. Tannenbaum C, Diaby V, Singh D, Perreault S, Luc M, Vasiliadis HM. Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. Drugs Aging. 2015 Apr; 32(4):305-14.
23. Adunlin G, Diaby V, Xiao H. Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis. Health Expect. 2015 Dec; 18(6):1894-905.
24. Diaby V, Goeree R, Hoch J, Siebert U. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb; 15(1):13-9.
25. Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.
26. Diaby V, Adunlin G, Zeichner SB, Avancha K, Lopes G, Gluck S, Montero AJ. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):433-41.
27. Adunlin G, Diaby V, Montero AJ, Xiao H. Multicriteria decision analysis in oncology. Health Expect. 2015 Dec; 18(6):1812-26.
28. Diaby V, Adunlin G, Montero AJ. Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88. J Med Econ. 2014 Apr; 17(4):248-9.
29. Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014 Feb; 32(2):101-8.
30. Diaby V, Goeree R. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb; 14(1):81-99.
31. Goeree R, Diaby V. Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? Best Pract Res Clin Gastroenterol. 2013 Dec; 27(6):831-44.
32. Diaby V, Lachaine J. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d''Ivoire. Appl Health Econ Health Policy. 2011 Nov 01; 9(6):389-402.
33. Diaby V, Dié Kakou H, Lachaine J. Eliciting preferences for reimbursed drugs selection criteria in Côte d''Ivoire. Patient. 2011; 4(2):125-31.
34. Diaby V, Perreault S, Lachaine J. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. Maturitas. 2007 Oct 20; 58(2):138-49.

Research Resources icon

Publications Timeline

Top MeSH Keywords

Tree Map of Keyword Semantic Groups (Categories)

Left-click a node to move down the tree, right-click the graph to move back up the tree

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile:
 
Keyword
Last Name
Institution
 
See all (3) people See all (60) people Search for (10) people
Feedback

RTRN Collaboration and Professional Networking Feedback